20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Arcutis Biotherapeutics Inc (ARQT) operates in the BIOTECHNOLOGY industry and is headquartered in Westlake Village, United States with about 354 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, ARQT reported $376M in revenue and ($16M) in net income.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Interactive charts & full statements → Open the ARQT valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $464M | $376M | $197M | $60M | $4M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $424M | $339M | $177M | $55M | $3M | ($1M) | $0M | $0M | — | — |
| Gross Margin % | 91.4% | 90.2% | 90.3% | 91.6% | 79.5% | — | — | — | — | — |
| Operating Income (EBIT) | $34M | ($12M) | ($128M) | ($241M) | ($302M) | ($207M) | ($137M) | ($43M) | ($20M) | ($4M) |
| Operating Margin % | 7.3% | -3.2% | -65.3% | -404.5% | -8183.0% | — | — | — | — | — |
| Net Income | $28M | ($16M) | ($140M) | ($262M) | ($311M) | ($206M) | ($136M) | ($42M) | ($19M) | ($5M) |
| Net Margin % | 6.0% | -4.3% | -71.2% | -439.8% | -8449.8% | — | — | — | — | — |
| EBITDA | $44M | $2M | ($110M) | ($227M) | ($295M) | ($206M) | ($135M) | ($42M) | ($19M) | ($4M) |
| Earnings Per Share (EPS) | $0.21 | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.17 | $-3.80 | $-1.10 | $-0.53 | $-4.71 |
| Shares Outstanding (M) | 136M | 127M | 121M | 69M | 55M | 49M | 36M | 38M | — | 1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $130M | $105M | $130M | $99M | $82M | $66M | $71M | $45M |
| Gross Profit | $119M | $96M | $118M | $91M | $74M | $57M | $64M | $39M |
| Gross Margin % | 91.6% | 90.7% | 91.0% | 91.2% | 90.8% | 86.6% | 90.3% | 87.7% |
| Operating Income (EBIT) | $16M | ($9M) | $18M | $9M | ($15M) | ($25M) | ($8M) | ($39M) |
| Operating Margin % | 12.7% | -8.6% | 14.2% | 8.6% | -17.9% | -37.2% | -10.7% | -87.3% |
| Net Income | $15M | ($11M) | $17M | $7M | ($16M) | ($25M) | ($11M) | ($42M) |
| Net Margin % | 11.6% | -10.7% | 13.4% | 7.5% | -19.5% | -38.1% | -15.1% | -92.8% |
| EBITDA | $17M | ($6M) | $22M | $11M | ($12M) | ($19M) | ($4M) | ($33M) |
| Earnings Per Share (EPS) | $0.11 | $-0.09 | $0.13 | $0.06 | $-0.13 | $-0.20 | $-0.09 | $-0.33 |
| Shares Outstanding (M) | 136M | 129M | 136M | 133M | 127M | 126M | 121M | 124M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $39M | ($6M) | ($112M) | ($247M) | ($258M) | ($175M) | ($113M) | ($43M) | ($14M) | ($4M) |
| Capital Expenditures (CapEx) | $0M | $1M | $0M | $0M | $23M | $1M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $38M | ($6M) | ($112M) | ($247M) | ($281M) | ($176M) | ($113M) | ($43M) | ($14M) | ($4M) |
| FCF Margin % | 8.2% | -1.7% | -57.1% | -415.2% | -7623.4% | — | — | — | — | — |
| Dividends Paid | — | — | — | — | $123M | $72M | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $13M | $2M | $26M | ($2M) | $0M | ($30M) | ($1M) | ($35M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $1M | $5M | $0M |
| Free Cash Flow (FCF) | $12M | $2M | $26M | ($2M) | $0M | ($31M) | ($6M) | ($35M) |
| FCF Margin % | 9.6% | 2.1% | 20.2% | -1.8% | 0.3% | -47.1% | -8.1% | -77.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $489M | $433M | $349M | $341M | $449M | $408M | $298M | $107M | $51M | $4M |
| Cash & Cash Equivalents | $34M | $43M | $71M | $88M | $54M | $98M | $65M | $63M | $39M | $3M |
| Total Liabilities | $268M | $243M | $191M | $253M | $240M | $110M | $28M | $6M | $75M | $9M |
| Total Debt (Short + Long-Term) | $109M | $109M | $108M | $203M | $198M | $73M | $0M | $0M | $0M | $1M |
| Total Shareholders' Equity | $221M | $189M | $158M | $89M | $210M | $298M | $271M | $101M | ($24M) | ($5M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ARQT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms